Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

User Fee Bill Caught In Comey Firing Tidal Wave

Executive Summary

Senate committee forced to postpone mark-up of FDA user fee reauthorization legislation; drug pricing fight may be postponed by hearing pledge.

You may also be interested in...



The US Drug Pricing Hearing Pharma Wants

Senate hearing will examine drug delivery system, but industry still faces possibility of another public shaming about increasing drug costs.

The US Drug Pricing Hearing Pharma Wants

Senate hearing will examine drug delivery system, but industry still faces possibility of another public shaming about increasing drug costs.

NEJM Takes Aim At Expensive Accelerated Approval Drugs Amid Congressional Drug Pricing Debate

Authors propose imposing penalties on drugmakers who don't start confirmatory trials shortly after accelerated approval and additional discounts for public payers; proposals could pick up steam among congressional democrats amid their renewed call for lower drug prices.

Related Content

Topics

UsernamePublicRestriction

Register

PS120614

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel